Laboratorios Normon S.A.
26
0
0
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 26 trials
0%
0 trials in Phase 3/4
0%
9 of 0 completed trials have results
Key Signals
Enrollment reporting
Analytics
Activity Timeline
Global Presence
Clinical Trials (26)
Bioequivalence clinical trial of two formulations of loperamide.
Role: lead
Bioequivalence clinical trial of two formulations of dapagliflozin/metformin
Role: lead
Bioequivalence clinical trial of two formulations of edoxaban.
Role: lead
Bioequivalence clinical trial of two formulations of loperamide.
Role: lead
Bioequivalence clinical trial of two formulations of empagliflozin/metformin
Role: lead
Bioequivalence clinical trial of two formulations of linagliptin/metformin.
Role: lead
Bioequivalence clinical trial of two formulations of sacubitril/valsartan
Role: lead
Bioequivalence clinical trial of two formulations of hydrochlorothiazide.
Role: lead
Bioequivalence clinical trial of two formulations of ezetimibe/atorvastatin
Role: lead
Bioequivalence clinical trial of two formulations of apixaban
Role: lead
Bioequivalence clinical trial of two formulations of ezetimibe/atorvastatin
Role: lead
Bioequivalence clinical trial of two formulations of rosuvastatin/ezetimibe.
Role: lead
Bioequivalence clinical trial of two formulations of sacubitril/valsartan
Role: lead
Bioequivalence clinical trial of two formulations of loperamide.
Role: lead
Bioequivalence clinical trial of two formulations of dapagliflozin/metformin
Role: lead
Bioequivalence clinical trial of two formulations of linagliptin/metformin
Role: lead
Bioequivalence clinical trial of two formulations of Pregabalin 300 mg.
Role: lead
Bioequivalence clinical trial of two formulations of bilastine.
Role: lead
Bioequivalence clinical trial of two formulations of canagliflozin
Role: lead
Bioequivalence clinical trial of two formulations of linagliptin
Role: lead